COMMUNIQUÉS West-GlobeNewswire

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
21/02/2024
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of [...]
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
21/02/2024
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced [...]
SFWJ dba MedCana Adding to Portfolio with Acquisition of Cutting-Edge Cannabis Company
21/02/2024
Targeted company, based in Colombia, holds a unique cannabis genetics license AUSTIN, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via IBN – SFWJ dba MedCana , a leading holding company in the cannabis industry, reveals it [...]
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
21/02/2024
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms [...]
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
21/02/2024
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA ® – REDWOOD [...]
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
21/02/2024
Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- [...]
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
21/02/2024
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
21/02/2024
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( [...]
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
21/02/2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]
Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial
21/02/2024
Randomized controlled trial designed to evaluate the safety and effectiveness of the Route 92 Medical 0.088” HiPoint Reperfusion Catheter, part of the Monopoint Reperfusion System SAN MATEO, Calif., Feb. 21, 2024 (GLOBE [...]
REPEAT: New report exposes harmful impact of Ford government’s privatization scheme on local public hospitals: Health Coalition
21/02/2024
Attn: Assignment Editor TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing [...]
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
21/02/2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
21/02/2024
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
21/02/2024
CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
BioSyent Named to 2024 TSX Venture 50
21/02/2024
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top [...]
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
21/02/2024
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay to measure target [...]
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21/02/2024
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass [...]
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
21/02/2024
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
CervoMed to Participate in the BIO CEO and Investor Conference
21/02/2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will [...]

Pages